II. Indications: Advanced Lesions (previously treated with other Chemotherapy)
- Soft Tissue Sarcoma
- Liposarcoma
- Leiomyosarcoma (L-Type)
III. Mechanism
- Novel alkyating antineoplastic agent
- Tetrahydroisoquinoline alkaloid isolated from the Sea Squirt (Ecteinascidia turbinata)
- Binds DNA minor groove
- Blocks Nucleotide excision repair
- Results in DNA breaks, blocking cell growth and replication
IV. Pharmacokinetics
- Metabolism: CYP3A
V. Medications
- Lypholized powder for injection solution: 1 mg vial
VI. Dosing
- See other references for disease specific dosing protocols
- Administered via Central Line
- Premedication with Dexamethasone 20 mg IV given 30 min before infusion
VII. Adverse Effects
- Severe Neutropenia
- Rhabdomyolysis
- Hepatotoxicity
- Cardiomyopathy
VIII. Safety
- Avoid in Lactation
- Avoid in Pregnancy (all trimesters)
- Teratogenic
- Use reliable Contraception
- Monitoring
IX. Drug Interactions
- Strong CYP3A inhibitors
- Raise Trabectedin levels
- Strong CYP3A Inducers
- Lower Trabectedin levels